136 related articles for article (PubMed ID: 28806841)
1. Genetic Polymorphisms as Predictive Markers of Response to Growth Hormone Therapy in Children with Growth Hormone Deficiency.
Jung AM; Zenker M; Lißewski C; Schanze D; Wagenpfeil S; Rohrer TR
Klin Padiatr; 2017 Sep; 229(5):267-273. PubMed ID: 28806841
[No Abstract] [Full Text] [Related]
2. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
3. Correlation between exon 3 polymorphism of growth hormone receptor gene and the responses to rhGH therapy.
Wei Y; Zheng R; Zhou Y; Wang J; Bao P
Int J Clin Exp Pathol; 2015; 8(6):7371-7. PubMed ID: 26261638
[TBL] [Abstract][Full Text] [Related]
4. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children.
Pilotta A; Mella P; Filisetti M; Felappi B; Prandi E; Parrinello G; Notarangelo LD; Buzi F
J Clin Endocrinol Metab; 2006 Mar; 91(3):1178-80. PubMed ID: 16394090
[TBL] [Abstract][Full Text] [Related]
5. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
6. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
[TBL] [Abstract][Full Text] [Related]
7. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
Adetunji OR; MacFarlane IA; Javadpour M; Alfirevic A; Pirmohamed M; Blair JC
Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
[TBL] [Abstract][Full Text] [Related]
8. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism.
Bianchi A; Giampietro A; Tartaglione L; Chiloiro S; Gentilella R; Bima C; Anile C; Olivi A; Pontecorvi A; De Marinis L
J Neuroendocrinol; 2019 Apr; 31(4):e12692. PubMed ID: 30712287
[TBL] [Abstract][Full Text] [Related]
10. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients.
Mormando M; Chiloiro S; Bianchi A; Giampietro A; Angelini F; Tartaglione L; Nasto L; Milardi D; Formenti AM; Giustina A; De Marinis L
Clin Endocrinol (Oxf); 2016 Nov; 85(5):717-724. PubMed ID: 27437620
[TBL] [Abstract][Full Text] [Related]
12. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
14. The impact of the d3-growth hormone receptor (d3-GHR) polymorphism on the therapeutic effect of growth hormone replacement in children with idiopathic growth hormone deficiency in Poland.
Szmit-Domagalska J; Petriczko E; Drozdzynska M; Adler G; Horodnicka-Jozwa A; Ciechanowicz A; Walczak M
Neuro Endocrinol Lett; 2016 Sep; 37(4):282-288. PubMed ID: 27857044
[TBL] [Abstract][Full Text] [Related]
15. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
17. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
18. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults.
van der Klaauw AA; van der Straaten T; Baak-Pablo R; Biermasz NR; Guchelaar HJ; Pereira AM; Smit JW; Romijn JA
J Clin Endocrinol Metab; 2008 Jul; 93(7):2828-34. PubMed ID: 18397980
[TBL] [Abstract][Full Text] [Related]
19. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults.
Moyes VJ; Walker DM; Owusu-Antwi S; Maher KT; Metherell L; Akker SA; Monson JP; Clark AJ; Drake WM
Clin Endocrinol (Oxf); 2010 Jun; 72(6):807-13. PubMed ID: 20039885
[TBL] [Abstract][Full Text] [Related]
20. Validating genetic markers of response to recombinant human growth hormone in children with growth hormone deficiency and Turner syndrome: the PREDICT validation study.
Stevens A; Murray P; Wojcik J; Raelson J; Koledova E; Chatelain P; Clayton P;
Eur J Endocrinol; 2016 Dec; 175(6):633-643. PubMed ID: 27651465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]